Fig. 5.

hBD2 inhibited Kv1.3 channel currents and IL-2 production in T cells and PBMCs from healthy donors and psoriasis patients. a 44.3 ± 3.0 and 43.4 ± 3.0 % of Kv1.3 channel currents were inhibited by 1 nM hBD2 in T cells from healthy donors which were untreated (upper) and pretreated (lower) by 100 ng/ml PTX for 2 h. b hBD2 suppressing IL-2 production in T cells from healthy donors. In the absence of hBD2, the amounts of IL-2 were 1,407.0 ± 82.7 pg/ml and 1,180.1 ± 98.4 pg/ml without and with PTX addition, respectively. c hBD2 suppressing IL-2 production in PBMCs from healthy donors. In the absence of hBD2, the amounts of IL-2 were 600.4 ± 35.5 and 383.5 ± 27.3 pg/ml without and with PTX addition, respectively. d 53.3 ± 0.5 and 49.8 ± 0.4 % of Kv1.3 channel currents were inhibited by 1 nM hBD2 in T cells from psoriasis patients which were untreated (upper) and pretreated (lower) by 100 ng/ml PTX for 2 h. e hBD2 suppressing IL-2 production in T cells from psoriasis patients. In the absence of hBD2, the amounts of IL-2 were 1,422.5 ± 45.2 and 1,294.1 ± 100.1 pg/ml without and with PTX addition, respectively. f hBD2 suppressing IL-2 production in PBMCs from psoriasis patients. In the absence of hBD2, amounts of IL-2 were 466.5 ± 27.1 and 383.1 ± 18.6 pg/ml without and with PTX addition, respectively. The data shown are the mean ± SD from three independent experiments; statistically significant inhibitions compared to the lack of drug treatment are determined using Student’s t test. (*p < 0.05, **p < 0.01)